Search
Wortmannin
go.drugbank.com/drugs/DB08059ExperimentalThis drug acts as a nonspecific, covalent inhibitor of phosphoinositide 3-kinase enzymes (PI3Ks).
Moexipril
go.drugbank.com/drugs/DB00691ApprovedInvestigationalMoexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen...
Alemtuzumab
go.drugbank.com/drugs/DB00087ApprovedInvestigational[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).
Indium In-111 oxyquinoline
go.drugbank.com/drugs/DB09473ApprovedIt is therefore useful in nuclear medicine, and is used in the labeling of leukocytes for localization of processes to which leukocytes migrate, such as those associated with abscesses or other infections
OC-1012
go.drugbank.com/drugs/DB05834ExperimentalOC-1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of mucositis, a serious side effect of chemotherapy and head and neck radiation therapy.
3-Allylfentanyl
go.drugbank.com/drugs/DB09169ExperimentalIllicitFentanyl and its analogs have killed thousands of people around the world as drugs of abuse.
Caramiphen
go.drugbank.com/drugs/DB11504ExperimentalVet approvedAdditionally, it is used, in combination with [phenylpropanolamine], as a cough suppressant and nasal decongestant for the symptomatic treatment of seasonal respiratory conditions.
2,4-Dinitrophenol
go.drugbank.com/drugs/DB04528ExperimentalIt is also used as a metabolic stimulant. (Stedman, 26th ed)
Citraconic acid
go.drugbank.com/drugs/DB04734ExperimentalCitraconic acid is one of the isomeric dicarboxylic acids produced by the distillation of citric acid, or as metabolites by microorganisms, cis-CH3-C(CO2H)=CHCO2H; the trans-isomer is mesaconic acid.
Zilebesiran
go.drugbank.com/drugs/DB18929InvestigationalZilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care